Bullous Pemphigoid Antigens (180 kDa and 230 kDa), IgG
ARUP test code 0092566

Bullous Pemphigoid Antigens, IgG

See Note

IMMUNODERMATOLOGY REPORT

Specimen(s):
1. Hemolyzed serum specimen

Clinical/diagnostic Information:
No clinical information provided.

___________________________________________________________

DIAGNOSTIC INTERPRETATION

Normal IgG Bullous Pemphigoid Antigens, BP 180 and IgG BP 230, antibody levels by ELISAs

(See Results and Comments including with attention to the interpretation relating to hemolyzed serum specimen and additional test recommendations)

___________________________________________________________

RESULTS

Enzyme Linked Immunosorbent Assay (ELISA)

Bullous Pemphigoid (BP) 180 and 230 IgG Antibodies

IgG BP 180 antibodies: 2 units

Reference Range:
Positive (H) = Greater than or equal to 9 units
Negative = Less than 9 units

IgG BP 230 antibodies: 1 unit

Reference Range:
Positive (H) = Greater than or equal to 9 units
Negative = Less than 9 units

(H = high/increased; units = units/mL serum)

COMMENTS
Specific

This specimen showed visible evidence of hemolysis upon receipt in the Immunodermatology Laboratory which could be associated with anomalous test results. Interpretation of the findings should take this potential into consideration with retesting of a non-hemolyzed serum specimen if the findings do not correspond to the clinical presentation and as recommended.

H=High, L=Low, *=Abnormal, C=Critical
Patients with pemphigoid may show reactivity to multiple basement membrane zone components other than the BP 180 and BP 230 epitopes expressed in these ELISAs; therefore, these normal results do not rule out a diagnosis of pemphigoid. These results also do not rule out treated or evolving pemphigoid or other immunobullous diseases. Clinical correlation is needed including with direct immunofluorescence on a biopsy specimen and treatment status.

Serum testing for IgG and IgA basement membrane zone antibodies by indirect immunofluorescence or, more broadly, for IgG and IgA basement membrane zone and cell surface antibodies by indirect immunofluorescence and additional ELISAs can provide further immunopathological/diagnostic information. To further evaluate the immunopathological profile in this patient’s serum, repeat and additional testing with a newly submitted, non-hemolyzed serum specimen is recommended, including for:

Basement membrane zone antibody-associated diseases (pemphigoid and pemphigoid variants, epidermolysis bullosa acquisita, and linear IgA disease including linear IgA bullous dermatosis) with
- IgG Epithelial Basement Membrane Zone Antibody (ARUP test number 0092056) and
- IgG Epithelial Basement Membrane Zone Antibody (ARUP test number 0092057) and
- IgG Collagen Type VII antibodies by ELISA (ARUP test number 2010905)
  or
Basement membrane zone and cell surface antibody-associated diseases (pemphigoid and pemphigoid variants, epidermolysis bullosa acquisita, linear IgA disease including linear IgA bullous dermatosis, and pemphigus and pemphigoid variants) with
- Epithelial Skin Antibody Panel (ARUP test number 0090299) and
- IgG Desmoglein 1 and IgG Desmoglein 3 Antibodies (ARUP test number 0090649) and/or
- IgG Collagen Type VII antibodies by ELISA (ARUP test number 2010905).

Detection, patterns, and levels of diagnostic antibodies may fluctuate with disease manifestations. Monitoring antibody profiles by indirect immunofluorescence as well as antibody levels by ELISAs may aid in assessing disease expression and activity.

General

Major molecular structures in the basement membrane zone to which IgG pemphigoid antibodies bind have been identified and termed “BP180” for a 180 kDa bullous pemphigoid antigen and “BP 230” for a 230 k Da bullous pemphigoid antigen. BP 180 is a transmembrane component of the basement membrane zone with collagen-like domains. BP 230 is located in the hemidesmosomal plaque of basal cells in the epidermis. Serum levels of IgG BP 180 and IgG BP 230 antibodies are in the normal range in normal individuals, and serum levels of IgG BP 180 antibodies correlate with disease activity in some patients with pemphigoid, diminishing in response to therapy.

TESTING METHODS

Enzyme Linked Immunosorbent Assay (ELISA)

IgG BP 180 and IgG BP 230 serum antibody levels determined by U.S. Food and Drug Administration-approved ELISAs (Mesacup, MBL BION).

[ITwo ELISAs]

Kristin M Leiferman, MD
Immunodermatologist
Electronically signed 5/31/2019 5:40:12AM

H=High, L=Low, *=Abnormal, C=Critical
EER Bullous Pemphigoid Antigens, IgG

See Note
Access ARUP Enhanced Report using either link below:
- Direct access:
- Enter Username, Password:
  Username:
  Password:

Performed at: ARUP - University Hospital Laboratory 50 N.
Medical Drive Salt Lake City UT 84132

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Accession</th>
<th>Collected</th>
<th>Received</th>
<th>Verified/Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullous Pemphigoid Antigens, IgG</td>
<td>19-144-402244</td>
<td>00/00/0000 00:00</td>
<td>00/00/0000 00:00</td>
<td>00/00/0000 00:00</td>
</tr>
<tr>
<td>EER Bullous Pemphigoid Antigens, IgG</td>
<td>19-144-402244</td>
<td>00/00/0000 00:00</td>
<td>00/00/0000 00:00</td>
<td>00/00/0000 00:00</td>
</tr>
</tbody>
</table>

END OF CHART